Search

Objective This meta-analysis aims to investigate the diagnostic performance of serum homocysteine (Hcy) as a biomarker for diabetic nephropathy (DN).

This meta-analysis assessed the association between myasthenia gravis (MG) and cognitive disorders. The PubMed, Web of Science, OVID, EMBASE, CNKI and Wanfang electronic databases were comprehensively searched from inception to October 2020 for relevant studies. The primary outcomes were scores of the cognitive function battery. A random effects model was used to evaluate the cognitive function of patients with MG. Eight cross-sectional studies containing 381 patients and 220 healthy controls were included in this meta-analysis. In relation to global cognitive function, patients with MG performed significantly worse than healthy individuals (SMD = −0.4, 95% CI = −0.63 to −0.16, p < 0.001, I2 = 10%). Specifically, the impaired cognitive domains included language, visuospatial function, information processing, verbal immediate and delayed recall memory, visual immediate recall memory, and response fluency, while attention, executive function, and visual delayed recall memory were unimpaired. The patients with early-onset (SMD= −0.527, 95% CI = −0.855 to −0.199, p = 0.002) and generalized MG (SMD= −0.577, 95% CI = −1.047 to −0.107, p = 0.016) had poorer global cognitive performance than the healthy population. Patients with MG may have cognitive disorders, including those associated with the domains of language, visuospatial function, information processing, verbal immediate and delayed recall memory, visual immediate recall memory and response fluency. Furthermore, the age of onset and disease severity may be associated with cognitive disorders in patients with MG. [ABSTRACT FROM AUTHOR]

Background: Migraine is a worldwide epidemic neurological disorder that has a significant influence on the quality of life. Migraine attacks are considered to be related to a calcitonin gene‐related peptide (CGRP) signaling molecule, and anti‐CGRP medications are used to abort and prevent migraine attacks. Erenumab, a monoclonal antibody that targets the CGRP receptor, is the first migraine preventive medication approved by the US Food and Drug Administration. In the present study, we evaluate the efficacy and safety of erenumab. Objective: This study aims to systematically assess the efficacy and safety of erenumab as a migraine preventive treatment compared to a placebo. Methods: Randomized, placebo‐controlled, single or double‐blind trials were searched through MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov up to May 2022. The efficacy outcomes we collected include changes from baseline on monthly migraine days, monthly acute migraine‐specific medication days, ≥50% responder rate, ≥75% responder rate, and 100% responder rate at week 12. Safety outcomes include treatment emergent adverse events, serious adverse events, and any adverse event that leads to discontinuation of treatment. The study was registered with PROSPERO (Registry number: CRD42022338861). Result: In all eight included trials, we found that erenumab (28, 70, and 140 mg) is very effective and has a significantly greater reduction in baseline monthly migraine days (28 mg: mean difference [MD] = −1.1, 95% confidence interval [CI]: −2.0 to −0.2, p = 0.020; 70 mg: MD = −1.4, 95% CI: −1.8 to −1.1, p < 0.001, I2 = 26%; 140 mg: MD = −1.8, 95% CI: −2.1 to −1.4, p < 0.001, I2 = 0%) than placebo at week 12, especially with 140 mg. Otherwise, we found that there were no statistical differences in the occurrence of adverse events (7 mg: risk ratio [RR] = 0.9, 95% CI: 0.7 to 1.2, p = 0.570; 21 mg: RR = 1.0, 95% CI: 0.8 to 1.2, p = 0.730; 28 mg: RR = 0.9, 95% CI: 0.7 to 1.1, p = 0.340; 70 mg: RR = 1.0, 95% CI: 0.9 to 1.0, p = 0.230, I2 = 0%; 140 mg: RR = 1.0, 95% CI: 0.9 to 1.1, p = 0.880, I2 = 40%) between the erenumab and placebo groups. Conclusions: In our study, we found that erenumab, especially at the dose of 140 mg, is an effective and well‐tolerated preventive treatment for migraine. [ABSTRACT FROM AUTHOR]

Objective: The studies have produced contradictory results regarding the association between myasthenia gravis (MG) and cognitive function, especially for the cognitive domains of memory. This meta-analysis was dedicated to exploring the association between MG and memory, which was represented by the immediate recall and delayed recall. Methods: Using the random effects models, this study analyzed memory in MG based on data from the studies retrieved from four electronic databases from inception to February 2021. Disease severity was graded according to the Myasthenia Gravis Foundation of America (MGFA) classification. We defined ocular myasthenia gravis (OMG) (MGFA Grade I) as Class I, mild, and moderate generalized myasthenia gravis (GMG) (MGFA Grade IIa, IIb, IIIa, and IIIb) as Class II. Results: In total, eight studies of 274 patients and 211 healthy controls were included. The significant associations were found between MG and memory. Compared with the healthy control group, the patients with MG performed significantly worse in the terms of immediate recall [standardized mean difference (SMD) = −0.65, 95% CI = −0.97 to −0.33, P < 0.001, I 2 = 64.1%] and delayed recall (SMD = −0.49, 95% CI = −0.88 to −0.1, P < 0.05, I 2 = 76.3%). Compared with the patients with Class I MG, those with Class II MG did not have significantly different scores in immediate recall (SMD = −0.07, 95% CI = −0.35 to 0.21, P = 0.614, I 2 = 0%) and delayed recall (SMD = 0.63, 95% CI = −0.29 to 1.55, P = 0.178, I 2 = 87.9%). Conclusion: The patients with MG showed lower memory performance, such as both immediate and delayed recall ability. There was no association between the severity of MG and memory. Future studies should address whether these associations are casual and modifiable. [ABSTRACT FROM AUTHOR]

Galectin-3 has an important function in the development of tumors. The purpose of this meta-analysis was to explore the relationships between the expression of galectin-3 on clinicopathological features and prognosis of colorectal cancer (CRC). A comprehensive literature search was used to identify eligible studies, and Stata software was conducted using in this meta-analysis. A total of 15 studies, including 1661 cases, were matched in the inclusion criteria. The pooled analysis indicated that galectin-3 expression was related to the poor overall survival (OS) in CRC patients (HR: 1.77, 95% CI: 1.36–2.31, P < 0.0001). Our meta-analysis also showed that cancerous tissues have higher levels of galectin-3 expression than normal tissues. Besides, positive galectin-3 expression was also related to advanced TNM stages(III/IV vs. I/II: OR 5.30, 95% CI: 2.42–11.61, P < 0.0001), higher Duke's stages (C/D vs. A/B: OR 4.00, 95% CI: 2.22–7.22, P < 0.0001), venous invasion (venous invasion vs. not: OR 3.02, 95%CI: 1.75–5.22, P < 0.0001) and higher CEA level (CEA≥5 ng/ml vs. ≤ 5 ng/ml: OR 2.09, 95% CI: 1.09–4.03, P = 0.03). In summary, our results indicated that overexpression of galectin-3 is significantly related to the tumor progression and could be a efficient in predicting the prognosis of patients with CRC. [ABSTRACT FROM AUTHOR]